<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360476</url>
  </required_header>
  <id_info>
    <org_study_id>1R01MD005849-01A1</org_study_id>
    <nct_id>NCT01360476</nct_id>
  </id_info>
  <brief_title>Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients</brief_title>
  <acronym>AdDReaCH</acronym>
  <official_title>Adjunct Vitamin D Therapy as a Means to Reduce the Disparity in Subclinical Target Organ Cardiac Damage Among Vulnerable Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project seeks to reduce the disparity in hypertensive heart disease which exists for&#xD;
      African-Americans who have poorly controlled hypertension (HTN), also known as blood pressure&#xD;
      (BP). The investigators are targeting a highly vulnerable, often neglected subject population&#xD;
      which stands to benefit tremendously from better BP control and a corresponding decrease in&#xD;
      heart damage. HTN occurs early in life and more often in African-Americans, reducing both&#xD;
      quality and quantity of life. Inner-city African-Americans with HTN utilize the emergency&#xD;
      department (ED) for chronic BP management. Like cardiovascular disease, vitamin D deficiency&#xD;
      disproportionately affects African-Americans. Vitamin D is thought to play an important role&#xD;
      in cardiovascular health. Vitamin D replacement in those who are deficient has been thought&#xD;
      to reduce the cardiovascular disease, especially if initiated early before irreversible&#xD;
      damage has occurred, but this has yet to be tested in a prospective clinical trial.&#xD;
      Accordingly, this proposal was designed to investigate the relationship between vitamin D and&#xD;
      cardiac damage (as identified on cardiac magnetic resonance imaging) in a cohort of&#xD;
      African-American, vitamin D deficient hypertensive patients without prior history of heart&#xD;
      disease.&#xD;
&#xD;
      The primary objective of this proposal is to evaluate the efficacy of vitamin D therapy in&#xD;
      vitamin D deficient African-Americans with HTN. Vitamin D is an inexpensive treatment, which,&#xD;
      if shown to be effective could improve the existing approach to a widely accessible,&#xD;
      cost-effective option.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in left ventricular hypertrophy at 1 year</measure>
    <time_frame>baseline, 16weeks, 52weeks</time_frame>
    <description>Cardiac MRI will be used to assess this change.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">354</enrollment>
  <condition>Hypertension</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol (Vitamin D)</intervention_name>
    <description>50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>chewable wafer every 2 weeks for 52 weeks (27 total doses)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with known HTN&#xD;
&#xD;
          -  African-American race (self reported)&#xD;
&#xD;
          -  Repeat SBP â‰¥ 160 mmHg within 1 hour of arrival&#xD;
&#xD;
          -  Age 30-74 years&#xD;
&#xD;
          -  Asymptomatic state (class I as defined by Goldman Specific Activity Scale)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dyspnea (exertional, rest or nocturnal) or chest pain as a primary or secondary chief&#xD;
             complaint&#xD;
&#xD;
          -  Prior history of HF, coronary artery disease, myocardial infarction, cardiomyopathy&#xD;
             (any), valvular heart disease (any) or renal failure with current, previous, or&#xD;
             planned future dialysis&#xD;
&#xD;
          -  Acute illness or injury which necessitates hospital admission&#xD;
&#xD;
          -  Acute alcohol or cocaine intoxication or history of chronic alcohol (determined using&#xD;
             the CAGE screening questions) or cocaine (self-reported) abuse&#xD;
&#xD;
          -  Acute or decompensated psychiatric disorder or any underlying psychiatric disorder or&#xD;
             cognitive deficit which precludes effective on-going communication or ability to&#xD;
             follow-up as required&#xD;
&#xD;
          -  Cancer (other than skin), HIV, or any other medical condition that might limit life&#xD;
             expectancy&#xD;
&#xD;
          -  Hepatitis or liver enzyme (ALT, AST) elevations &gt; 1.5x normal&#xD;
&#xD;
          -  Planned move &gt; 50 miles in the next 9 months&#xD;
&#xD;
          -  History of kidney stones&#xD;
&#xD;
          -  GFR &lt;30&#xD;
&#xD;
          -  Serum calcium &gt; 10.5 mg/dl or known history of hypercalcemia&#xD;
&#xD;
          -  History of or known primary hyperparathyroidism&#xD;
&#xD;
          -  Sarcoidosis or other granulomatous disease&#xD;
&#xD;
          -  Pregnant or planning to become pregnant&#xD;
&#xD;
          -  Allergy or known hypersensitivity to gadolinium contrast&#xD;
&#xD;
          -  Severe claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip D Levy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Phillip D. Levy</investigator_full_name>
    <investigator_title>Associate Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>African-Americans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

